anti-Nipah_253
| anti-Nipah_ID | anti-Nipah_253 |
| anti-Nipah Drug | (2R,3R,4S,5R)-2-(4-Aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydro-2-furancarbonitrile |
| Nipah virus strain | NiV (Bangladesh-2004) |
| Approaches used to test anti-Nipah activity | Experimental |
| Methods used to test anti-Nipah activity | In-vitro |
| Models used to test anti-Nipah activity | HeLA |
| Mode of infection to test anti-Nipah activity | Adsorption |
| Viral titer to test anti-Nipah activity | 0.25 TCID50 |
| Mode of Drug delivery for anti-Nipah activity | Culture |
| Time of Drug delivery for anti-Nipah activity | Post Infection |
| Duration of Drug delivery for anti-Nipah activity | 48 hours |
| Drug concentration used to test anti-Nipah activity | 0.83 μM |
| Assays used to test anti-Nipah activity | TCID50 |
| anti-Nipah activity | Decrease [Effective concentration (50 %)] |
| Cytotoxicity of anti-Nipah compounds | >50 _M |
| References | Lo MK, Jordan R, Arvey A, Sudhamsu J, Shrivastava-Ranjan P, Hotard AL, Flint M, McMullan LK, Siegel D, Clarke MO, Mackman RL, Hui HC, Perron M, Ray AS, Cihlar T, Nichol ST, Spiropoulou CF GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci Rep. 2017 Mar 6;7:43395. doi: 10.1038/srep43395. |
| Comments | Antiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, providing evidence to support new indications for this compound against human viruses of significant public health concern. |